Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors
Graphical abstract
Section snippets
Acknowledgements
The authors wish to thank Dr. Charles W. Ross III for obtaining HRMS data and Dr. Sandor Varga for NMR work to identify and characterize the regioisomeric quinoxalines and pyrazinones.
References and notes (13)
- et al.
FASEB
(1995)et al.Clin. Cancer Res.
(2001) - et al.
Tetrahedron Lett.
(2002)et al.Tetrahedron
(2002) Expert Opin. Ther. Targets
(2002)et al.Cell. Signal.
(2002)et al.Curr. Top. Med. Chem.
(2002)- et al.
Oncogene
(2002)et al.Anticancer Res.
(2000) - et al.
Proc. Natl. Acad. Sci. U.S.A.
(1996)et al.Curr. Biol.
(1998)Proc. Natl. Acad. Sci. U.S.A.
(1987)et al.Cancer Res.
(2001) - et al.
J. Am. Chem. Soc.
(2003)
There are more references available in the full text version of this article.
Cited by (486)
An efficient synthetic route of quinoxalines from diols catalyzed by [RuCl<inf>2</inf>(p-cymene)]<inf>2</inf>/1,4-bis(diphenylphosphino)butane
2023, Journal of Organometallic ChemistryIndoles Oxidative Ring-Opening/Cyclization Cascade with the 1,2-Diaminoarenes: Direct Synthesis of 2-Aryl-3-(2-aminoaryl)quinoxalines
2022, Journal of Organic ChemistryOne-pot synthesis of novel substituted quinoxaline piperazine derivatives and their antimicrobial activities
2022, Journal of Molecular StructureAkt inhibitors in cancer therapy
2022, Protein Kinase Inhibitors: From Discovery to Therapeutics
Copyright © 2004 Elsevier Ltd. All rights reserved.